Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
Richard D. Carvajal(Northwell Health), Gary K. Schwartz(Baylor University Medical Center), Patrick J. Flynn(American Society of Clinical Oncology), J. Fernando Quevedo(Mayo Clinic), Ragini R. Kudchadkar, Mark J. Bluth(Memorial Sloan Kettering Cancer Center), Grazia Ambrosini(Cancer Research Center), Mark R. Albertini(University of Wisconsin–Madison), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Brian P. Marr(Memorial Sloan Kettering Cancer Center), Jose Lutzky, Joseph P. Erinjeri(Memorial Sloan Kettering Cancer Center), David H. Abramson(Memorial Sloan Kettering Cancer Center), Takami Sato(Thomas Jefferson University), Jedd D. Wolchok(Cornell University), David H. Lawson(Emory University), Austin Doyle(National Cancer Institute), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Kristin Kathleen Ancell(Vanderbilt University Medical Center), Cyrus V. Hedvat(Memorial Sloan Kettering Cancer Center), Gerald P. Linette(University of Pennsylvania), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Thomas F. Gajewski(University of Chicago), Anthony M. Joshua(St Vincent's Hospital Sydney), Mohammed Milhem(University of Iowa), Katherine S. Panageas(Mayo Clinic), Christopher D. Lao(University of Michigan), Karl D. Lewis(University of Colorado Denver)
Cited by 429
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k